The five main types of lung cancer are adenocarcinoma, squamous cell carcinoma, large cell carcinoma, small cell lung cancer, and carcinoid tumors. Adenocarcinoma (about 40 percent of cases) starts in mucus-producing gland cells, while squamous cell carcinoma (25 to 30 percent) arises in the flat cells lining the airways. Large cell carcinoma (5 to 10 percent) is a diagnosis of exclusion. Small cell lung cancer (10 to 15 percent) grows fast and is tied to smoking. Carcinoid tumors (1 to 2 percent) are slow-growing neuroendocrine growths. These figures follow the 2021 WHO Classification of Thoracic Tumours.
What Cancer Type Means Inside the Lung
Lung cancer is not one disease wearing five costumes. The type describes which cell of origin went wrong, and that cell's normal job determines where the tumor grows, how fast it divides, and which drugs can reach it. A gland cell that secretes mucus keeps its secretory machinery when it turns malignant. A flat airway-lining cell keeps its layered, protective architecture. Those structural differences become treatment targets.
This is why pathologists, not oncologists, decide the first fork in care. Every diagnosis is a cell-identity question. The answer determines whether a patient receives surgery, chemotherapy, immune therapy, or a targeted pill. Lung cancer kills more people worldwide than any other cancer, per the World Health Organization, which is what makes correct subtype classification so consequential.
In plain terms: the type tells doctors what the cancer was before it was cancer, and that origin dictates the plan.
How the Five Types Differ by Origin and Share
Adenocarcinoma starts in the glands that line the small airways and produce mucus. It is the most common type in the United States and the most common in people who never smoked. It often begins at the lung's outer edge, which is why it can sit silently for years. Nearly 40 percent of all lung cancers are adenocarcinomas.
Squamous cell carcinoma starts in the flat cells of the large airway branches near the center of the chest. It has a strong smoking link and tends to appear near the bronchi, where it can cause bleeding or airway blockage. Historically it was the most common type; its share fell as cigarette filters and smoking patterns changed.
Large cell carcinoma is a catch-all. It is diagnosed only when a tumor shows no gland, no flat-cell, and no small-cell features under the microscope. That makes it rare and shrinking, because modern molecular testing can usually reclassify it. Some tumors once called large cell are now identified as poorly differentiated adenocarcinomas or squamous tumors.
Small cell lung cancer arises from neuroendocrine cells that carry hormone-like signaling machinery. It is almost always smoking-related, grows quickly, and is usually found after it has spread. It accounts for roughly 10 to 15 percent of cases.
Carcinoid tumors are the outlier. They also come from neuroendocrine cells but grow slowly and behave far more gently. They account for 1 to 2 percent of lung cancers and often arise in the central airways.
The Numbers Behind Each Diagnosis
The quantified differences matter more than the labels.
| Type | Share of lung cancers | Typical location | Growth speed | 5-year survival (all stages) |
|---|---|---|---|---|
| Adenocarcinoma | ~40% | Outer lung (periphery) | Moderate | ~30% |
| Squamous cell carcinoma | 25–30% | Central airways | Moderate to fast | ~25% |
| Large cell carcinoma | 5–10% | Variable, often periphery | Fast | ~15–20% |
| Small cell lung cancer | 10–15% | Central, near main bronchi | Very fast | ~7% |
| Carcinoid tumor | 1–2% | Central airways | Slow | ~90% |
Survival numbers are pooled across all stages and lag behind current treatment, so they understate today's outcomes. The gap between carcinoid at roughly 90 percent and small cell at roughly 7 percent is the sharpest single fact in lung cancer classification. It shows how much cell of origin controls behavior.
The Timeline from First Exposure to Diagnosis
Lung cancer has a long fuse. The timeline below sketches the typical course for a smoking-related tumor, with the caveat that individual cases vary widely.
| Stage | Typical time | What is happening |
|---|---|---|
| Initiation | Year 0 | Tobacco carcinogens mutate airway cells |
| Promotion | Years 5–20 | Mutated clones expand, still invisible on imaging |
| Preclinical growth | Years 2–5 | Tumor reaches 1 cm, roughly 1 billion cells |
| Detectable on CT | Any time after ~1 cm | Screening CT can catch it |
| Symptoms | Often stage III–IV | Cough, blood, weight loss appear |
| Average metastasis window | Months | Small cell can spread in under a year from a small primary |
Doubling times vary enormously: small cell lung cancer can double in as little as 30 days, while carcinoid tumors may take a year or more. In plain terms: the same lung, the same smoke, but wildly different clocks.
Why Small Cell and Non-Small Cell Split Treatment
The single most practical divide is small cell versus non-small cell, not five equal categories. Small cell lung cancer is treated primarily with chemotherapy plus radiation, because it is chemosensitive but rarely surgical by the time it is found. The non-small cell group, which covers adenocarcinoma, squamous, and large cell, is treated by stage and by molecular profile.
Among non-small cell tumors, molecular testing drives everything. About 15 to 25 percent of adenocarcinomas carry an EGFR mutation in never-smokers, and roughly 3 to 5 percent carry an ALK rearrangement, per the 2021 WHO classification and major oncology guidelines. These tumors respond to targeted pills with response rates above 60 percent, far exceeding the 20 to 30 percent seen with standard chemotherapy. Squamous tumors rarely carry these mutations, so the test is usually skipped there.
The non-obvious caveat: an adenocarcinoma in a 45-year-old never-smoker is more likely to harbor a druggable mutation than the same tumor in a 70-year-old heavy smoker. Smoking history changes the molecular yield, not just the risk.
Misconceptions That Cost Time
The most dangerous myth is that only smokers get lung cancer. In the United States, roughly 10 to 20 percent of lung cancers occur in people who never smoked, and adenocarcinoma dominates that group. Screening guidelines still center on smoking history, which means never-smokers are usually not screened at all.
A second misconception is that a "large cell" diagnosis is final. Modern pathology can reclassify many such tumors through immunohistochemistry, a stain-based test that flags cell lineage. A tumor called large cell in 2005 might be called adenocarcinoma today.
A third is that all lung cancers are equally fast. Carcinoid tumors can smolder for a decade, while small cell tumors can double within a month. Treating them as one disease leads to the wrong urgency and the wrong treatment.
Warning Signs That Should Trigger a Scan
Symptoms overlap across types, but some patterns point to specific histology. These warrant prompt evaluation, not watchful waiting:
- A persistent cough lasting more than three weeks, especially with blood-streaked sputum
- Unexplained weight loss of 10 pounds or more over three months
- New shortness of breath during ordinary activity
- Chest pain that worsens with deep breathing
- Recurrent pneumonia or bronchitis in the same lung region
- Facial swelling or hoarseness suggesting airway or nerve involvement
Blood in sputum more often flags central tumors, such as squamous or small cell. A silent nodule found incidentally on imaging more often flags peripheral adenocarcinoma.
What to Actually Do After a Suspicious Scan
The next step is not a lung cancer diagnosis. It is a tissue diagnosis, and the order of operations matters. Request a low-dose CT if you meet screening criteria: age 50 to 80, at least a 20 pack-year smoking history, and current smoking or quitting within the past 15 years, per 2021 US Preventive Services Task Force guidance. A pack-year is one pack daily for a year; 20 pack-years means a pack a day for two decades.
If a nodule is found, ask for a size-specific follow-up plan rather than a vague repeat scan. Nodules under 6 millimeters in low-risk patients often need no immediate action; nodules over 8 millimeters usually prompt PET imaging or biopsy. For a confirmed adenocarcinoma, ask whether molecular testing for EGFR, ALK, ROS1, and PD-L1 has been ordered before any treatment starts. That test can redirect care within two weeks.
Where the Classification Still Fails
The five-type framework is a map, not the territory. Many tumors are mixed, and up to 10 percent of non-small cell tumors are classified as not otherwise specified when tissue is scarce. The WHO classification continues to evolve; the 2021 edition added detail to adenocarcinoma grading that was absent a decade earlier.
The practical limitation is that the label alone does not predict response. Two adenocarcinomas with identical histology can carry completely different mutations and behave as separate diseases. The type is the starting address; the molecular profile is the actual route.